



CLIENT CODE: C000138354
CLIENT'S NAME AND ADDRESS:

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030

PATIENT NAME: GEETANJALI SETHI

<u>Final</u>

NEW DELHI 1100 DELHI INDIA 8800465156

Test Report Status

SRL Ltd

Shop CG 017, PALM SPRINGS PLAZA

GURUGRAM, 122001 HARYANA, INDIA Tel: 9111591115

PATIENT ID: GEETF210670282

Biological Reference Interval Units

ACCESSION NO: **0282VK002109** AGE: 52 Years SEX: Female ABHA NO:

DRAWN: RECEIVED: 28/11/2022 08:41:16 REPORTED: 29/11/2022 12:31:04

Results

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

BLOOD COUNTS,EDTA WHOLE BLOOD				
HEMOGLOBIN (HB)	11.6	Low	12.0 - 15.0	g/dL
METHOD: SPECTROPHOTOMETRY				
RED BLOOD CELL (RBC) COUNT	4.67		3.8 - 4.8	mil/μL
METHOD: IMPEDANCE				
WHITE BLOOD CELL (WBC) COUNT	9.48		4.0 - 10.0	thou/µL
METHOD: IMPEDANCE				
PLATELET COUNT	381		150 - 410	thou/µL
METHOD: IMPEDANCE				
RBC AND PLATELET INDICES				
HEMATOCRIT (PCV)	35.0	Low	36 - 46	%
METHOD: CALCULATED				
MEAN CORPUSCULAR VOLUME (MCV)	74.9	Low	83 - 101	fL
METHOD: DERIVED FROM IMPEDANCE MEASURE				
MEAN CORPUSCULAR HEMOGLOBIN (MCH)	24.8	Low	27.0 - 32.0	pg
METHOD: CALCULATED PARAMETER				
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION (MCHC) METHOD: CALCULATED PARAMETER	33.1		31.5 - 34.5	g/dL
RED CELL DISTRIBUTION WIDTH (RDW)	17.1	High	11.6 - 14.0	%
METHOD: DERIVED FROM IMPEDANCE MEASURE				
MENTZER INDEX	16.0			
MEAN PLATELET VOLUME (MPV)	8.1		6.8 - 10.9	fL
METHOD : DERIVED FROM IMPEDANCE MEASURE				
WBC DIFFERENTIAL COUNT				
NEUTROPHILS	60		40 - 80	%
METHOD: DHSS FLOWCYTOMETRY				
YMPHOCYTES	32		20 - 40	%
METHOD : DHSS FLOWCYTOMETRY				
MONOCYTES	6		2 - 10	%
METHOD: DHSS FLOWCYTOMETRY				
OSINOPHILS	2		1 - 6	%
METHOD: DHSS FLOWCYTOMETRY				
BASOPHILS	0		0 - 2	%
METHOD : IMPEDANCE				









CLIENT CODE: C000138354
CLIENT'S NAME AND ADDRESS:

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI

NEW DELHI 110030 DELHI INDIA 8800465156 SRL Ltd Shop CG 017, PALM SPRINGS PLAZA

GURUGRAM, 122001 HARYANA, INDIA Tel: 9111591115

PATIENT NAME: GEETANJALI SETHI PATIENT ID: GEETF210670282

ACCESSION NO: **0282VK002109** AGE: 52 Years SEX: Female ABHA NO:

DRAWN: RECEIVED: 28/11/2022 08:41:16 REPORTED: 29/11/2022 12:31:04

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status	<u>Final</u>	Results		Biological Reference Interva	l Units
ABSOLUTE NEUTROPHI	L COUNT	5.66		2.0 - 7.0	thou/µL
METHOD : DHSS FLOWCYTO	METRY, CALCULATED				
ABSOLUTE LYMPHOCYT	E COUNT	3.04	High	1 - 3	thou/µL
METHOD : DHSS FLOWCYTO	METRY, CALCULATED				
ABSOLUTE MONOCYTE	COUNT	0.55		0.20 - 1.00	thou/µL
METHOD : DHSS FLOWCYTO	METRY, CALCULATED				
ABSOLUTE EOSINOPHI	L COUNT	0.22		0.02 - 0.50	thou/µL
METHOD : DHSS FLOWCYTO	METRY, CALCULATED				
ABSOLUTE BASOPHIL	COUNT	0.01	Low	0.02 - 0.10	thou/µL
METHOD : DHSS FLOWCYTO	METRY, CALCULATED				
NEUTROPHIL LYMPHOC	CYTE RATIO (NLR)	1.9			
METHOD : CALCULATED					
ERYTHROCYTE SEDII	MENTATION RATE (ESR),WI	HOLE			
E.S.R		29	Hiah	0 - 20	mm at 1 hr
	DTOMETRICAL CAPILLARY STOPPED FLOW	_		0 20	mm ac 1 m
•	IOGLOBIN(HBA1C), EDTA W	•			
BLOOD	odlobin(libate), LDTA W	HOLL			
HBA1C METHOD: CAPILLARY ELECT	TPOPHORESIS	6.9	High	Non-diabetic: < 5.7 Pre-diabetics: 5.7 - 6.4 Diabetics: > or = 6.5 ADA Target: 7.0 Action suggested: > 8.0	%
ESTIMATED AVERAGE		151.3	Hiah	< 116	mg/dL
LOTIMATED AVERAGE	GLUCUSL(LAG)	151.5	ıngıı	< 110	ilig/uL



METHOD: CALCULATED PARAMETER







CLIENT CODE: C000138354
CLIENT'S NAME AND ADDRESS:

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI

SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156 SRL Ltd

Shop CG 017, PALM SPRINGS PLAZA

GURUGRAM, 122001 HARYANA, INDIA Tel: 9111591115

PATIENT NAME: GEETANJALI SETHI PATIENT ID: GEETF210670282

ACCESSION NO: **0282VK002109** AGE: 52 Years SEX: Female ABHA NO:

DRAWN: RECEIVED: 28/11/2022 08:41:16 REPORTED: 29/11/2022 12:31:04

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status <u>Final</u> Results Biological Reference Interval Units


PLOT NO.31, ELECTRONIC CITY, SECTOR 18, GURUGRAM

ID: 28212503783

Name :

Sample Date: 11/29/2022

Sample num.: 3



A1c Haemoglobin Electrophoresis

Fractions	%	mmol/mol	Cal. %
Hb A1c	-	51	6.9
Other Hb A	2.6		
Hb A0	88.9		
Hb A2	1.8		

HbA1c % cal :6.9 % >

Comments:









CLIENT CODE: C000138354
CLIENT'S NAME AND ADDRESS:

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI

SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156 SRL Ltd

Shop CG 017, PALM SPRINGS PLAZA

GURUGRAM, 122001 HARYANA, INDIA Tel: 9111591115

PATIENT NAME: GEETANJALI SETHI PATIENT ID: GEETF210670282

ACCESSION NO: **0282VK002109** AGE: 52 Years SEX: Female ABHA NO:

DRAWN: RECEIVED: 28/11/2022 08:41:16 REPORTED: 29/11/2022 12:31:04

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status <u>Final</u>	Results		Biological Reference Interv	al Units
GLUCOSE FASTING, FLUORIDE PLASMA				
FBS (FASTING BLOOD SUGAR)	106	High	Normal 75 - 99 Pre-diabetics: 100 - 125 Diabetic: > or = 126	mg/dL
METHOD: SPECTROPHOTOMETRY HEXOKINASE				
GLUCOSE, POST-PRANDIAL, PLASMA				
PPBS(POST PRANDIAL BLOOD SUGAR) METHOD: SPECTROPHOTOMETRY, HEXOKINASE	169	High	70 - 139	mg/dL
LIPID PROFILE, SERUM				
CHOLESTEROL, TOTAL	118		Desirable cholesterol level < 200 Borderline high cholesterol 200 - 239 High cholesterol > / = 240	mg/dL
METHOD: ENZYMATIC COLORIMETRIC ASSAY				
TRIGLYCERIDES	134		Normal: < 150 Borderline high: 150 - 199 High: 200 - 499 Very High: >/= 500	mg/dL
METHOD: ENZYMATIC COLORIMETRIC ASSAY				
HDL CHOLESTEROL	36	Low	Low HDL Cholesterol <40	mg/dL
			High HDL Cholesterol >/= 60	ס
METHOD: HOMOGENEOUS ENZYMATIC COLORIMETRIC ASS	SAY			
CHOLESTEROL LDL	56		Adult levels: Optimal < 100 Near optimal/above optimal: 129 Borderline high: 130-159 High: 160-189 Very high: = 190	mg/dL 100-
METHOD: HOMOGENEOUS ENZYMATIC COLORIMETRIC ASS	SAY			
NON HDL CHOLESTEROL	82		Desirable: < 130 Above Desirable: 130 -159 Borderline High: 160 - 189 High: 190 - 219 Very high: > / = 220	mg/dL
METHOD: CALCULATED PARAMETER				
CHOL/HDL RATIO	3.0	Low	Low Risk: 3.3 - 4.4 Average Risk: 4.5 - 7.0 Moderate Risk: 7.1 - 11.0	



Page 4 Of 15

 $High \; Risk: > 11.0$





GEETF210670282

CLIENT CODE: C000138354 **CLIENT'S NAME AND ADDRESS:**

8800465156

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA

SRL Ltd Shop CG 017, PALM SPRINGS PLAZA GURUGRAM, 122001

PATIENT ID:

HARYANA, INDIA Tel: 9111591115

PATIENT NAME: GEETANJALI SETHI

ACCESSION NO: **0282VK002109** AGE: 52 Years SEX: Female ABHA NO:

RECEIVED: 28/11/2022 08:41:16 29/11/2022 12:31:04 DRAWN: REPORTED:

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status <u>Final</u>	Results		Biological Reference	Interval Units
METHOD : CALCULATED PARAMETER	1.6		O.F. 2.O.Dasimable/Law	v Diale
LDL/HDL RATIO	1.6		0.5 - 3.0 Desirable/Low Risk 3.1 - 6.0 Borderline/Moderate Risk >6.0 High Risk	
METHOD : CALCULATED PARAMETER	26.0		. OD 20.0	
VERY LOW DENSITY LIPOPROTEIN	26.8		< OR = 30.0	mg/dL
METHOD : CALCULATED PARAMETER				
LIVER FUNCTION PROFILE, SERUM	0.0			
BILIRUBIN, TOTAL	0.3		Upto 1.2	mg/dL
METHOD : COLORIMETRIC DIAZO METHOD	0.2		. 0. 20	
BILIRUBIN, DIRECT	0.2		< 0.30	mg/dL
METHOD : COLORIMETRIC DIAZO METHOD	0.10		0.1 1.0	/ 41
BILIRUBIN, INDIRECT	0.10		0.1 - 1.0	mg/dL
METHOD : CALCULATED PARAMETER	7.9		6.0 - 8.0	a /dl
TOTAL PROTEIN METHOD: SPECTROPHOTOMETRY, BIURET	7.9		0.0 - 0.0	g/dL
ALBUMIN	4.5		3.97 - 4.94	g/dL
METHOD : SPECTROPHOTOMETRY, BROMOCRESOL GREEN(BCG)			3.37 - 4.34	g/uL
GLOBULIN	3.4		2.0 - 3.5	g/dL
METHOD : CALCULATED PARAMETER	5.4		2.0 3.5	9/42
ALBUMIN/GLOBULIN RATIO	1.3		1.0 - 2.1	RATIO
METHOD : CALCULATED PARAMETER	1.5		110 211	101120
ASPARTATE AMINOTRANSFERASE (AST/SGOT)	26		< OR = 35	U/L
METHOD : SPECTROPHOTOMETRY, WITH PYRIDOXAL PHOSPHATE				3, =
ALANINE AMINOTRANSFERASE (ALT/SGPT)	26		< OR = 35	U/L
METHOD: SPECTROPHOTOMETRY, WITH PYRIDOXAL PHOSPHATE	E ACTIVATION-IFCC			,
ALKALINE PHOSPHATASE	116	High	35 - 104	U/L
METHOD: SPECTROPHOTOMETRY, PNPP, AMP BUFFER - IFCC				
GAMMA GLUTAMYL TRANSFERASE (GGT)	17		0 - 40	U/L
METHOD: ENZYMATIC COLORIMETRIC ASSAY STANDARDIZED A	AGAINST IFCC / SZASZ			
LACTATE DEHYDROGENASE	128		125 - 220	U/L
METHOD: SPECTROPHOTOMETRY, LACTATE TO PYRUVATE - UV-I	IFCC			
BLOOD UREA NITROGEN (BUN), SERUM				
BLOOD UREA NITROGEN	12.5		6 - 20	mg/dL
METHOD: SPECTROPHOTOMETRY, KINETIC TEST WITH UREASE	AND GLUTAMATE DEHYDRO	GENASE		-
CREATININE, SERUM				
CREATININE	0.70		0.5 - 0.9	mg/dL
				J .









CLIENT CODE: C000138354
CLIENT'S NAME AND ADDRESS:

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI

SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156 SRL Ltd

Shop CG 017, PALM SPRINGS PLAZA

GURUGRAM, 122001 HARYANA, INDIA Tel: 9111591115

PATIENT NAME: GEETANJALI SETHI PATIENT ID: GEETF210670282

ACCESSION NO: 0282VK002109 AGE: 52 Years SEX: Female ABHA NO:

DRAWN: RECEIVED: 28/11/2022 08:41:16 REPORTED: 29/11/2022 12:31:04

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status	<u>Final</u>	Results		Biological Referen	ce Interval Units
METHOD: SPECTROPHOTOM	ETRIC, JAFFE'S KINETIC	S			
BUN/CREAT RATIO					
BUN/CREAT RATIO		18.00	High	8.0 - 15.0	
METHOD : CALCULATED PAR	AMETER				
URIC ACID, SERUM					
URIC ACID		5.6		2.4 - 5.7	mg/dL
METHOD : SPECTROPHOTOM	ETRY, URICASE				
TOTAL PROTEIN, SE	RUM				
TOTAL PROTEIN		7.9		6.0 - 8.0	g/dL
METHOD: SPECTROPHOTOM	ETRY, BIURET				
ALBUMIN, SERUM					
ALBUMIN		4.5		3.97 - 4.94	g/dL
METHOD: SPECTROPHOTOM	ETRY, BROMOCRESOL G	REEN(BCG) - DYE BINDING			
GLOBULIN					
GLOBULIN		3.4		2.0 - 3.5	g/dL
METHOD : CALCULATED PAR	AMETER				
ELECTROLYTES (NA/	K/CL), SERUM				
SODIUM, SERUM		138		136 - 145	mmol/L
METHOD : ISE INDIRECT					
POTASSIUM, SERUM		4.1		3.5 - 5.1	mmol/L
METHOD : ISE INDIRECT					
CHLORIDE, SERUM		101		98 - 107	mmol/L
METHOD : ISE INDIRECT					
Interpretation(s)					

PHYSICAL EXAMINATION, URINE

COLOR PALE YELLOW APPEARANCE TURBID

Comments

NOTE :MICROSCOPIC EXAMINATION OF URINE IS PERFORMED ON CENTRIFUGED URINARY SEDIMENT.

IN NORMAL URINE SAMPLES CAST AND CRYSTALS ARE NOT DETECTED.

CHEMICAL EXAMINATION, URINE

PH 6.5 4.7 - 7.5



Page 6 Of 15





CLIENT CODE: C000138354 **CLIENT'S NAME AND ADDRESS:**

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI **NEW DELHI 110030**

DELHI INDIA 8800465156 SRL Ltd Shop CG 017, PALM SPRINGS PLAZA GURUGRAM, 122001

HARYANA, INDIA Tel: 9111591115

PATIENT NAME: GEETANJALI SETHI PATIENT ID: GEETF210670282

SEX : Female ACCESSION NO: **0282VK002109** AGE: 52 Years ABHA NO:

RECEIVED: 28/11/2022 08:41:16 29/11/2022 12:31:04 DRAWN: REPORTED:

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status <u>Final</u>	Results	Biological Reference Interv	al Units
SPECIFIC GRAVITY	<=1.005	1.003 - 1.035	
PROTEIN	NOT DETECTED	NOT DETECTED	
GLUCOSE	NOT DETECTED	NOT DETECTED	
KETONES	NOT DETECTED	NOT DETECTED	
BLOOD	DETECTED (TRACE)	NOT DETECTED	
BILIRUBIN	NOT DETECTED	NOT DETECTED	
UROBILINOGEN	NORMAL	NORMAL	
NITRITE	NOT DETECTED	NOT DETECTED	
LEUKOCYTE ESTERASE	DETECTED(+++)	NOT DETECTED	
MICROSCOPIC EXAMINATION, URINE			
RED BLOOD CELLS	1 - 2	NOT DETECTED	/HPF
PUS CELL (WBC'S)	20-30	0-5	/HPF
EPITHELIAL CELLS	8-10	0-5	/HPF
CASTS	NOT DETECTED		
CRYSTALS	NOT DETECTED		
BACTERIA	DETECTED (FEW)	NOT DETECTED	
METHOD: DIP STICK/MICRO SCOPY/REFLECTANCE SPECTROPHO	TOMETRY		
Interpretation(s)			
THYROID PANEL, SERUM			
ТЗ	125.0	80 - 200	ng/dL
METHOD: ELECTROCHEMILUMINESCENCE IMMUNO ASSAY			<u>.</u>
T4	9.60	5.1 - 14.1	μg/dL
METHOD: ELECTROCHEMILUMINESCENCE IMMUNO ASSAY			
TSH (ULTRASENSITIVE)	2.860	0.27 - 4.2	μIU/mL
METHOD: ELECTROCHEMILUMINESCENCE IMMUNO ASSAY			









CLIENT CODE: C000138354 **CLIENT'S NAME AND ADDRESS:**

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI **NEW DELHI 110030**

SRL Ltd Shop CG 017, PALM SPRINGS PLAZA GURUGRAM, 122001 HARYANA, INDIA

Tel: 9111591115

PATIENT NAME: GEETANJALI SETHI PATIENT ID: GEETF210670282

AGE: 52 Years SEX · Female ACCESSION NO: 0282VK002109 ABHA NO:

DRAWN: RECEIVED: 28/11/2022 08:41:16 REPORTED: 29/11/2022 12:31:04

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Results **Test Report Status** Biological Reference Interval Units **Final**

Interpretation(s)

DELHI INDIA 8800465156

Triiodothyronine T3, Thyroxine T4, and Thyroid Stimulating Hormone TSH are thyroid hormones which affect almost every physiological process in the body, including growth, development, metabolism, body temperature, and heart rate.

Production of T3 and its prohormone thyroxine (T4) is activated by thyroid-stimulating hormone (TSH), which is released from the pituitary gland. Elevated concentrations of T3, and T4 in the blood inhibit the production of TSH.

Excessive secretion of thyroxine in the body is hyperthyroidism, and deficient secretion is called hypothyroidism.

In primary hypothyroidism, TSH levels are significantly elevated, while in secondary and tertiary hyporthyroidism, TSH levels are low. owidctlparowidctlparBelow mentioned are the guidelines for Pregnancy related reference ranges for Total T4, TSH & Total T3. Measurement of the serum TT3 level is a more sensitive test for the diagnosis of hyperthyroidism, and measurement of TT4 is more useful in the diagnosis of hypothyroidism. Most of the thyroid hormone in blood is bound to transport proteins. Only a very small fraction of the circulating hormone is free and biologically active. It is advisable to detect Free T3, FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.

Sr. No.	TSH	Total T4	FT4	Total T3	Possible Conditions
1	High	Low	Low	Low	(1) Primary Hypothyroidism (2) Chronic autoimmune Thyroiditis (3)
					Post Thyroidectomy (4) Post Radio-Iodine treatment
2	High	Normal	Normal	Normal	(1)Subclinical Hypothyroidism (2) Patient with insufficient thyroid
					hormone replacement therapy (3) In cases of Autoimmune/Hashimoto
					thyroiditis (4). Isolated increase in TSH levels can be due to Subclinical
					inflammation, drugs like amphetamines, Iodine containing drug and
					dopamine antagonist e.g. domperidone and other physiological reasons.
3	Normal/Low	Low	Low	Low	(1) Secondary and Tertiary Hypothyroidism
4	Low	High	High	High	(1) Primary Hyperthyroidism (Graves Disease) (2) Multinodular Goitre
					(3)Toxic Nodular Goitre (4) Thyroiditis (5) Over treatment of thyroid
					hormone (6) Drug effect e.g. Glucocorticoids, dopamine, T4
					replacement therapy (7) First trimester of Pregnancy
5	Low	Normal	Normal	Normal	(1) Subclinical Hyperthyroidism
6	High	High	High	High	(1) TSH secreting pituitary adenoma (2) TRH secreting tumor
7	Low	Low	Low	Low	(1) Central Hypothyroidism (2) Euthyroid sick syndrome (3) Recent
					treatment for Hyperthyroidism
8	Normal/Low	Normal	Normal	High	(1) T3 thyrotoxicosis (2) Non-Thyroidal illness
9	Low	High	High	Normal	(1) T4 Ingestion (2) Thyroiditis (3) Interfering Anti TPO antibodies

REF: 1. TIETZ Fundamentals of Clinical chemistry 2. Guidlines of the American Thyroid association during pregnancy and Postpartum, 2011. NOTE: It is advisable to detect Free T3, FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.TSH is not affected by variation in thyroid - binding protein. TSH has a diurnal rhythm, with peaks at 2:00 - 4:00 a.m. And troughs at 5:00 - 6:00 p.m. With ultradian variations.

STOOL: OVA & PARASITE

RFMARK METHOD: MICROSCOPIC EXAMINATION SUSCEPTIBILITY TEST CANCELLED AS CULTURE WAS NEGATIVE

Interpretation(s)



Page 8 Of 15 Scan to View Report





CLIENT CODE: C000138354 **CLIENT'S NAME AND ADDRESS:**

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI

SOUTH WEST DELHI **NEW DELHI 110030**

DELHI INDIA 8800465156 SRL Ltd

Shop CG 017, PALM SPRINGS PLAZA

GURUGRAM, 122001 HARYANA, INDIA Tel: 9111591115

PATIENT NAME: GEETANJALI SETHI PATIENT ID: GEETF210670282

ACCESSION NO: 0282VK002109 AGE: 52 Years SEX · Female ABHA NO:

DRAWN: RECEIVED: 28/11/2022 08:41:16 REPORTED: 29/11/2022 12:31:04

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Results **Test Report Status** Biological Reference Interval Units **Final**

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD

0 ABO GROUP

METHOD: HEMAGGLUTINATION REACTION ON SOLID PHASE

RH TYPF RH+

METHOD: HEMAGGLUTINATION REACTION ON SOLID PHASE

XRAY-CHEST

BOTH THE LUNG FIELDS ARE CLEAR **»**»

BOTH THE COSTOPHRENIC AND CARDIOPHRENIC ANGLES ARE CLEAR **»**»

BOTH THE HILA ARE NORMAL

CARDIAC AND AORTIC SHADOWS APPEAR NORMAL BOTH THE DOMES OF THE DIAPHRAGM ARE NORMAL

IMPRESSION NO ABNORMALITY DETECTED

TMT OR ECHO

TMT OR ECHO ECHO REPORT

Normal sized cardiac chambers and normal valves

Trivial MR, Trivial TR

VISUALIZED BONY THORAX IS NORMAL

No RWMA

Normal LV systolic function LVEF \sim 60 % Grade I LV diastolic dysfunction, E<A No Clot/Vegetation/Pericardial Effusion IVS/IAS intact, no flow seen across.

ECG

ECG NSR, TINVERSION IN V1-V4

MEDICAL HISTORY

RELEVANT PRESENT HISTORY HYPERTENSION - 10 YEARS

RELEVANT PAST HISTORY NOT SIGNIFICANT

RELEVANT PERSONAL HISTORY MARRIED TWO CHILDREN PERI MENOPAUSAL

LMP (FOR FEMALES) 2 MONTHS AGO RELEVANT FAMILY HISTORY HIGH BP - PARENTS **DIABETES - MOTHER**

OCCUPATIONAL HISTORY HOMEMAKER

HISTORY OF MEDICATIONS UNDER TREATMENT

ANTHROPOMETRIC DATA & BMI

HEIGHT IN METERS 1.62 mts









CLIENT CODE: C000138354
CLIENT'S NAME AND ADDRESS:

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI

SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156 SRL Ltd

Shop CG 017, PALM SPRINGS PLAZA

GURUGRAM, 122001 HARYANA, INDIA Tel: 9111591115

PATIENT NAME: GEETANJALI SETHI PATIENT ID: GEETF210670282

ACCESSION NO: **0282VK002109** AGE: 52 Years SEX: Female ABHA NO:

DRAWN: RECEIVED: 28/11/2022 08:41:16 REPORTED: 29/11/2022 12:31:04

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

	CELENT / VIZENT IS 1			
Test Report Status <u>Final</u>	Results	Biological Reference Interval Units		
WEIGHT IN KGS.	80	Kgs		
ВМІ	30	BMI & Weight Status as follows: kg/sqmts Below 18.5: Underweight 18.5 - 24.9: Normal 25.0 - 29.9: Overweight 30.0 and Above: Obese		
GENERAL EXAMINATION				
MENTAL / EMOTIONAL STATE	NORMAL			
PHYSICAL ATTITUDE	NORMAL			
GENERAL APPEARANCE / NUTRITIONAL STATUS	OBESE			
BUILT / SKELETAL FRAMEWORK	AVERAGE			
FACIAL APPEARANCE	NORMAL			
SKIN	NORMAL			
UPPER LIMB	NORMAL			
LOWER LIMB	NORMAL			
NECK	NORMAL			
NECK LYMPHATICS / SALIVARY GLANDS	NOT ENLARGED OR TENDE	ER		
THYROID GLAND	NOT ENLARGED			
CAROTID PULSATION	NORMAL			
TEMPERATURE	NORMAL			
PULSE	82 / MIN REGULAR, ALL P BRUIT	ERIPHERAL PULSES WELL FELT, NO CAROTID		
RESPIRATORY RATE	NORMAL			
CARDIOVASCULAR SYSTEM				
ВР	150/96 MMHG (SUPINE)	mm/Hg		
PERICARDIUM	NORMAL			
APEX BEAT	NORMAL			
HEART SOUNDS	S1, S2 HEARD NORMALLY	•		
MURMURS	ABSENT			
RESPIRATORY SYSTEM				

SIZE AND SHAPE OF CHEST NORMAL

MOVEMENTS OF CHEST SYMMETRICAL

BREATH SOUNDS INTENSITY NORMAL

BREATH SOUNDS QUALITY VESICULAR (NORMAL)









CLIENT CODE: C000138354
CLIENT'S NAME AND ADDRESS:

ACROFEMI HEALTHCARE LTD (MEDIWHEEL)

F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156 SRL Ltd

Shop CG 017, PALM SPRINGS PLAZA

GURUGRAM, 122001 HARYANA, INDIA Tel: 9111591115

PATIENT NAME: GEETANJALI SETHI PATIENT ID: GEETF210670282

ACCESSION NO: 0282VK002109 AGE: 52 Years SEX: Female ABHA NO:

DRAWN: RECEIVED: 28/11/2022 08:41:16 REPORTED: 29/11/2022 12:31:04

REFERRING DOCTOR: SELF		CLIENT PATIENT ID:		
Test Report Status <u>Final</u>	Results	Biological Reference Interval Units		
ADDED SOUNDS	ABSENT			
PER ABDOMEN				
APPEARANCE	NORMAL			
VENOUS PROMINENCE	ABSENT			
LIVER	NOT PALPABLE			
SPLEEN	NOT PALPABLE			
CENTRAL NERVOUS SYSTEM				
HIGHER FUNCTIONS	NORMAL			
CRANIAL NERVES	NORMAL			
CEREBELLAR FUNCTIONS	NORMAL			
SENSORY SYSTEM	NORMAL			
MOTOR SYSTEM	NORMAL			
REFLEXES	NORMAL			

SPINE	NORMAL
JOINTS	NORMAL

BASIC EYE EXAMINATION

MUSCULOSKELETAL SYSTEM

DISTANT VISION RIGHT EYE WITH GLASSES 6/6
DISTANT VISION LEFT EYE WITH GLASSES 6/6
NEAR VISION RIGHT EYE WITH GLASSES N/6
NEAR VISION LEFT EYE WITH GLASSES N/6
COLOUR VISION 17/17

SUMMARY

REMARKS / RECOMMENDATIONS

ADVISED

LIFESTYLE CHANGES

REGULAR BP & BLOOD SUGAR RECORD

REPEAT URINE RE AFTER PLENTY OF ORAL FLUIDS,

FOLLOW UP WITH PHYSICIAN

& EYE SPECIALIST.

CONSULT GYAECOLOGIST IN VIEW OF USG FINDINGS.

REVIEW WITH ECG,CXR REPORTS.



Page 11 Of 15





CLIENT CODE: C000138354 **CLIENT'S NAME AND ADDRESS:**

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI

SOUTH WEST DELHI **NEW DELHT 110030 DELHI INDIA** 8800465156

Test Report Status

DRAWN:

SRL Ltd Shop CG 017, PALM SPRINGS PLAZA GURUGRAM, 122001

HARYANA, INDIA Tel: 9111591115

PATIENT NAME: GEETANJALI SETHI

PATIENT ID: GEETF210670282

ACCESSION NO: 0282VK002109

Final

AGE: 52 Years SEX · Female ARHA NO ·

Results

RECEIVED: 28/11/2022 08:41:16

REPORTED: 29/11/2022 12:31:04

CLIENT PATIENT ID:

REFERRING DOCTOR: SELF

Biological Reference Interval Units

MEDI WHEEL FULL BODY HEALTH CHECKUP ABOVE 40FEMALE **ULTRASOUND ABDOMEN ULTRASOUND ABDOMEN**

GRADE I FATTY CHANGES IN LIVER UTERINE FIBROID

Interpretation(s)

BLOOD COUNTS, EDTA WHOLE BLOOD-The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology.

RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13) from Beta thalassaemia trait

(<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for diagnosing a case of beta thalassaemia trait.

WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR = 3.4 (20.1%) covid-19 patients with mild disease might become severe. 3.3, COVID-19 patients tend to show mild disease.

(Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients; A.-P. Yang, et al.; International Immunopharmacology 84 (2020) 106504 This ratio element is a calculated parameter and out of NABL scope.

ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD-TEST DESCRIPTION :-

Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic; it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition.CRP is superior to ESR because it is more sensitive and reflects a more rapid change.

TEST INTERPRETATION

Increase in: Infections, Vasculities, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy, Estrogen medication, Aging.

Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias,

Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis). In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum. Decreased in: Polycythermia vera, Sickle cell anemia

LIMITATIONS

False elevated ESR: Increased fibrinogen, Drugs(Vitamin A, Dextran etc), Hypercholesterolemia
False Decreased: Poikilocytosis,(SickleCells,spherocytes),Microcytosis, Low fibrinogen, Very high WBC counts, Drugs(Quinine, salicylates)

REFERENCE

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition; 2, Paediatric reference intervals, AACC Press, 7th edition, Edited by S. Soldin; 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis, 10th edition. GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-**Used For**:

- 1. Evaluating the long-term control of blood glucose concentrations in diabetic patients.
- 2. Diagnosing diabetes.
- 3.Identifying patients at increased risk for diabetes (prediabetes).

The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patients metabolic control has remained continuously within the target range.

- 1.eAG (Estimated average glucose) converts percentage HbA1c to md/dl, to compare blood glucose levels.
- 2. eAG gives an evaluation of blood glucose levels for the last couple of months. 3. eAG is calculated as eAG (mg/dl) = 28.7 * HbA1c 46.7

HbA1c Estimation can get affected due to :

I.Shortened Erythrocyte survival: Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss, hemolytic anemia) will falsely lower HbA1c test results. Fructosamine is recommended in these patients which indicates diabetes control over 15 days. II. Vitamin C & E are reported to falsely lower test results. (possibly by inhibiting glycation of hemoglobin.





Scan to View Report





GEETF210670282

CLIENT CODE: C000138354 **CLIENT'S NAME AND ADDRESS:**

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI

SOUTH WEST DELHI **NEW DELHT 110030 DELHI INDIA** 8800465156

SRL Ltd Shop CG 017, PALM SPRINGS PLAZA GURUGRAM, 122001 HARYANA, INDIA

ARHA NO ·

PATIENT ID:

Tel: 9111591115

PATIENT NAME: GEETANJALI SETHI

AGE: 52 Years ACCESSION NO: 0282VK002109 SEX · Female

RECEIVED: 28/11/2022 08:41:16 REPORTED: 29/11/2022 12:31:04 DRAWN:

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Results Biological Reference Interval Test Report Status Units <u>Final</u>

III.Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates addiction are reported to interfere with some assay methods, falsely increasing results. IV.Interference of hemoglobinopathies in HbA1c estimation is seen in

a.Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c. b.Heterozygous state detected (D10 is corrected for HbS & HbC trait.)

c.HbF > 25% on alternate paltform (Boronate affinity chromatography) is recommended for testing of HbA1c.Abnormal Hemoglobin electrophoresis (HPLC method) is

recommended for detecting a hemoglobinopathy GLUCOSE FASTING,FLUORIDE PLASMA-**TEST DESCRIPTION**

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted in the urine.

Diabetes mellitus, Cushing's syndrome (10 – 15%), chronic pancreatitis (30%). Drugs:corticosteroids, phenytoin, estrogen, thiazides.

Decreased in

Pancreatic islet cell disease with increased insulin,insulinoma,adrenocortical insufficiency, hypopituitarism,diffuse liver disease, malignancy (adrenocortical, stomach,fibrosarcoma), infant of a diabetic mother, enzyme deficiency diseases(e.g., galactosemia),Drugs- insulin, ethanol, propranolol; sulfonylureas,tolbutamide, and other oral hypoglycemic agents

NOTE:

Hypoglycemia is defined as a glucoseof < 50 mg/dL in men and < 40 mg/dL in women.

While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within individuals. Thus, glycosylated hemoglobin (HbA1c) levels are favored to monitor glycemic control.

High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.

GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin

treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.Additional test HbA1c LIVER FUNCTION PROFILE, SERUM-

LIVER FUNCTION PROFILE

Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give yellow discoloration in jaundice. Elevated levels results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin when there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors &Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver, liver cancer, kidney failure, hemolytic anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attack or strenuous activity. ALT test measures the amount of this enzyme in the blood. ALT is found mainly in the liver, but also in smaller amounts in the kidneys, heart, muscles, and pancreas. It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health. AST levels increase during acute hepatitis, sometimes due to a viral infection, ischemia to the liver, chronic

hepatitis, obstruction of bile ducts, cirrhosis.

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Paget's disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia, Malnutrition, Protein deficiency, Wilson's disease. GGT is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, biliary system and pancreas. Conditions that increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc. Serum total protein, also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstrom's disease. Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc. Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular

permeability or decreased lymphatic clearance,malnutrition and wasting etc
BLOOD UREA NITROGEN (BUN), SERUM-Causes of Increased levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol,
Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism)
Causes of decreased level include Liver disease, SIADH.
CREATININE, SERUM-Higher than normal level may be due to:

- Blockage in the urinary tract
- Kidney problems, such as kidney damage or failure, infection, or reduced blood flow
 Loss of body fluid (dehydration)
- Muscle problems, such as breakdown of muscle fibers
- Problems during pregnancy, such as seizures (eclampsia)), or high blood pressure caused by pregnancy (preeclampsia)

Lower than normal level may be due to:

- Muscular dystrophy



Page 13 Of 15 Scan to View Report







GEETF210670282

CLIENT CODE: C000138354 **CLIENT'S NAME AND ADDRESS:**

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI

SOUTH WEST DELHI **NEW DELHI 110030 DELHI INDIA** 8800465156

SRL Ltd Shop CG 017, PALM SPRINGS PLAZA GURUGRAM, 122001 HARYANA, INDIA

PATIENT ID:

Tel: 9111591115

PATIENT NAME: GEETANJALI SETHI

ACCESSION NO: **0282VK002109** AGE: 52 Years SEX · Female ABHA NO:

DRAWN: RECEIVED: 28/11/2022 08:41:16 REPORTED: 29/11/2022 12:31:04

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Results **Biological Reference Interval Units** Test Report Status **Final**

URIC ACID, SERUM-

Causes of Increased levels:-Dietary(High Protein Intake, Prolonged Fasting, Rapid weight loss), Gout, Lesch nyhan syndrome, Type 2 DM, Metabolic syndrome Causes of decreased levels-Low Zinc intake, OCP, Multiple Sclerosis

TOTAL PROTEIN, SERUM-

Serum total protein, also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and

Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstrom's disease Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc.

ALBUMIN, SERUM-

Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance,malnutrition and wasting etc. ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-

Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same.

The test is performed by both forward as well as reverse grouping methods.

THIS REPORT CARRIES THE SIGNATURE OF OUR LABORATORY DIRECTOR. THIS IS AN INVIOLABLE FEATURE OF OUR LAB MANAGEMENT SOFTWARE. HOWEVER, ALL EXAMINATIONS AND INVESTIGATIONS HAVE BEEN CONDUCTED BY OUR PANEL OF DOCTORS.

End Of Report

Please visit www.srlworld.com for related Test Information for this accession



Page 14 Of 15





CLIENT CODE: C000138354
CLIENT'S NAME AND ADDRESS:

8800465156

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA SRL Ltd Shop CG 017, PALM SPRINGS PLAZA GURUGRAM, 122001 HARYANA, INDIA Tel: 9111591115

PATIENT NAME: GEETANJALI SETHI PATIENT ID: GEETF210670282

ACCESSION NO: **0282VK002109** AGE: 52 Years SEX: Female ABHA NO:

DRAWN: RECEIVED: 28/11/2022 08:41:16 REPORTED: 29/11/2022 12:31:04

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status Final Results Biological Reference Interval Units

CONDITIONS OF LABORATORY TESTING & REPORTING

- 1. It is presumed that the test sample belongs to the patient named or identified in the test requisition form.
- 2. All tests are performed and reported as per the turnaround time stated in the SRL Directory of Services.
- 3. Result delays could occur due to unforeseen circumstances such as non-availability of kits / equipment breakdown / natural calamities / technical downtime or any other unforeseen event.
- 4. A requested test might not be performed if:
 - i. Specimen received is insufficient or inappropriate
 - ii. Specimen quality is unsatisfactory
 - iii. Incorrect specimen type
 - iv. Discrepancy between identification on specimen container label and test requisition form

- 5. SRL confirms that all tests have been performed or assayed with highest quality standards, clinical safety & technical integrity.
- 6. Laboratory results should not be interpreted in isolation; it must be correlated with clinical information and be interpreted by registered medical practitioners only to determine final diagnosis.
- 7. Test results may vary based on time of collection, physiological condition of the patient, current medication or nutritional and dietary changes. Please consult your doctor or call us for any clarification.
- 8. Test results cannot be used for Medico legal purposes.
- 9. In case of queries please call customer care (91115 91115) within 48 hours of the report.

SRL Limited

Fortis Hospital, Sector 62, Phase VIII, Mohali 160062



